Dr May-Lucie Meyer speaks to ecancer about the development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma.

She explores the complexities of developing novel treatments for NSCLC and mesothelioma and details challenges like limited clinical data and the preclinical status of many agents.

She highlights that advancements in T-cell engager engineering could further the development of these agents as a novel treatment.

Dr Meyer emphasises the need for evidence-based progression, focusing on clinical utility and biomarker identification before large-scale trials.